-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $45

Benzinga·06/11/2026 11:55:10
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Buy rating and announces Price Target of $45.